Skip to main content
Fig. 1 | Alzheimer's Research & Therapy

Fig. 1

From: Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer’s disease: a systematic review

Fig. 1

Trial selection and use of fluid-based biomarker endpoints in clinical trials investigating Alzheimer disease-modifying treatments per development phase. Overview of the methods (A). Percentage of trials using a fluid-based biomarker (B). Percentage of trials using a fluid-based biomarkers as primary, primary and nonprimary, or nonprimary endpoint (C). Percentage of trials using CSF, blood or both (D)

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193